Camurus AB (FRA:7CA) FFO


FRA:7CA Camurus AB FRA:7CA
84 GF Score
Price €48.70
GF Value €62.28
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:7CA
84GF Score
Camurus AB FRA:7CA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (FRA:7CA) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of €48.70 is trading 21.8% below its estimated GF Value™ of €62.28. GuruFocus considers Camurus AB to be Modestly Undervalued.

Key valuation signals for FRA:7CA:

  • FFO:
  • GF Value™: €62.28 vs. price of €48.70 (21.8% below fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the FRA:7CA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
84GF Score

Get the complete analysis for FRA:7CA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.70
Price
€62.28
GF Value